abstract |
Combinations of Compound 1 or a pharmaceutically acceptable salt thereof (such as Compound 1-A) and Compound 2 or a pharmaceutically acceptable salt thereof (such as Compound 2-A) for treating a host infected with hepatitis C, as well as pharmaceuticals Compositions and dosage forms thereof, including solid dosage forms, are provided. |